Why GlucoTrack Shares Are Trading Higher By Around 118%; Here Are 20 Stocks Moving Premarket

Shares of GlucoTrack Inc (NASDAQ:GCTK) rose sharply in pre-market trading following the announcement that its subsidiary, Lokahi Therapeutics, signed its first external, fee-for-service partnership. Innovate GBM, a nonprofit dedicated to glioblastoma research, engaged two of Lokahi’s ai PIPELINE project teams to identify brain tumor therapeutic assets available for licensing and development. According to the announcement, the deal makes Innovate GBM the first outside organization to tap Lokahi’s proprietary asset-identification process, built on 14 university collaborations. GlucoTrack shares jumped 117.7% to $4.42 in pre-market trading Here are some other stocks moving in pre-market trading. Gainers Digital Currency X Technology Inc (NASDAQ:DCX) gained 117.3% to $0.16 in pre-market trading after dipping 30% on Wednesday. Digital Currency X Technology recently announced pricing of $5 million registered direct offering. Wetour Robotics Ltd (NASDAQ:WETO) rose 51.7% to $2.20 in pre-market trading after dropping 12% on Wednesday. Greenland Mines Ltd (NASDAQ:GRML) gained 32.8% to $14.86 in pre-market trading. Greenland Mines announced that it has raised over $42 million from existing investors through a registered direct offering of common stock and pre-funded warrants, and the exercise of previously issued private warrants. Springview Holdings Ltd (NASDAQ:SPHL) rose 27.4% to $2.94 in pre-market trading. Top Wealth Group Holding Ltd (NASDAQ:TWG) gained 16.8% to $0.31 in pre-market trading following a bullish profit alert from the Cayman Islands-based luxury goods company. Top Wealth said net profit attributable to shareholders is expected to rise at least 100% year-over-year for fiscal 2026. Stablecoin Development Corp (NYSE:SDEV) rose 14.3% to $1.28 in pre-market trading after dipping 12% on Wednesday. VerifyMe Inc (NASDAQ:VRME) gained 12.2% to $1.29 in pre-market trading after rising over 10% on Wednesday. Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) rose 10% to $14.63 in pre-market trading. Arcturus Therapeutics reported interim Phase 2 results from ARCT-810 in OTC deficiency and introduced LUNAR 2.0. The company also announced plans to acquire myNEO. Everpure Inc (NYSE:P) gained 5.9% to $116.05 in pre-market trading. Everpure reaffirmed FY27 revenue guidance of $5.03 billion-$5.07 billion and issued preliminary FY28 revenue outlook of $7 billion-$7.3 billion. Losers Beneficient (NASDAQ:BENF) tumbled 35.5% to $1.87 in pre-market trading. Beneficient shares jumped 439% on Wednesday after the company announced a strategy to eliminate HCLP debt and Heppner Equity Interests. VisionSys AI Inc (NASDAQ:VSA) fell 31.6% to $2.49 in pre-market trading after jumping 38% on Wednesday. Artelo Biosciences Inc (NASDAQ:ARTL) fell 28.7% to $5.20 in pre-market trading. Artelo Biosciences shares jumped 76% on Wednesday after the company announced the filing of a provisional patent application for ART27.13 as a monotherapy and in combination with GLP-1 receptor agonists. Arcadia Biosciences Inc (NASDAQ:RKDA) fell 28% to $0.31 in pre-market trading after declining 5% on Wednesday. 22nd Century Group Inc (NASDAQ:XXII) fell 23.5% to $1.79 in pre-market trading. 22nd Century Group shares jumped 29% on Wednesday following reports suggesting that U.S. regulators plan to speed authorizations of vapes and tobacco pouches. NeoVolta Inc (NASDAQ:NEOV) declined 21.7% to $2.48 in pre-market trading after the company reported fourth-quarter and fiscal year 2026 financial results. Stitch Fix Inc (NASDAQ:SFIX) fell 18.2% to $2.31 in pre-market trading after the company reported mixed fourth-quarter financial results and issued weak first-quarter sales guidance. Silexion Therapeutics Corp (NASDAQ:SLXN) fell 17.6% to $0.26 in pre-market trading after dipping 20% on Wednesday. MGM Resorts International (NYSE:MGM) fell 8.3% to $34.70 in pre-market trading. People Inc. announced that it has withdrawn its proposal to purchase all public shares of MGM Resorts International. Viking Therapeutics Inc (NASDAQ:VKTX) fell 8.3% to $38.19 in pre-market trading after the company announced a pair of proposed public offerings. Photo via Shutterstock